Updated: January 23, 2026
Retacrit Side Effects: What to Expect and When to Call Your Doctor
Author
Peter Daggett

Summarize with AI
- FDA Boxed Warning: Know These Risks
- Common Side Effects in CKD Patients
- Common Side Effects in Cancer Chemotherapy Patients
- Side Effects in Surgery Patients
- Serious Side Effects: When to Seek Emergency Care
- When to Call Your Doctor (Not an Emergency)
- Pure Red Cell Aplasia (PRCA): A Rare but Serious Risk
- The Bottom Line
Retacrit (epoetin alfa-epbx) can cause side effects ranging from high blood pressure to rare but serious risks. Here's what to watch for and when to call your doctor.
Retacrit (epoetin alfa-epbx) is an effective treatment for anemia, but like all medications — especially biologics — it carries risks that patients need to understand. This guide covers the most common side effects, the serious risks highlighted in the FDA's boxed warning, and clear guidance on when to seek medical attention.
FDA Boxed Warning: Know These Risks
Retacrit carries the FDA's most serious warning — a Boxed Warning (also called a "black box warning"). This is required for all ESAs and covers the following critical risks:
- Increased risk of death, heart attack, stroke, and blood clots. Clinical trials showed higher rates of these events in patients treated to hemoglobin targets greater than 11 g/dL. This is why your doctor carefully monitors your hemoglobin and uses the lowest effective dose.
- Increased risk of tumor progression or recurrence in cancer patients. ESAs have been shown to shorten overall survival and increase tumor progression in studies of patients with breast cancer, non-small cell lung cancer, head and neck cancer, lymphoid cancers, and cervical cancer. Retacrit should only be used in cancer patients receiving myelosuppressive chemotherapy for non-curative intent.
Common Side Effects in CKD Patients
In clinical studies of patients with chronic kidney disease, the following side effects occurred in 5% or more of patients receiving epoetin alfa:
- High blood pressure (hypertension) — the most common side effect; approximately 25% of dialysis patients required new or increased antihypertensive therapy after starting Retacrit
- Joint pain (arthralgia)
- Muscle spasm
- Fever (pyrexia)
- Dizziness
- Upper respiratory tract infection (cold symptoms)
- Vascular occlusion (blood clots in dialysis access, deep veins)
Common Side Effects in Cancer Chemotherapy Patients
In cancer patients receiving chemotherapy, side effects occurring in 5% or more of patients included:
- Nausea and vomiting
- Muscle pain (myalgia) and joint pain (arthralgia)
- Mouth sores (stomatitis)
- Cough
- Weight loss
- Low white blood cell count (leukopenia)
- Bone pain, rash, high blood sugar, insomnia, headache, depression, thrombosis
Side Effects in Surgery Patients
For patients taking Retacrit before or after elective surgery to reduce the need for blood transfusions, common side effects (occurring in ≥5%) include:
- Nausea, vomiting, and itching (pruritus)
- Headache and chills
- Injection site pain
- Deep vein thrombosis (DVT)
- High blood pressure and cough
Serious Side Effects: When to Seek Emergency Care
Call 911 or go to the emergency room immediately if you experience:
- Chest pain, pressure, or tightness (possible heart attack)
- Sudden weakness, numbness, or difficulty speaking (possible stroke)
- Sudden shortness of breath or leg swelling/pain (possible blood clot / pulmonary embolism)
- Seizure or new onset of convulsions
- Severe allergic reaction: rash, hives, throat swelling, difficulty breathing
When to Call Your Doctor (Not an Emergency)
Contact your prescriber if you notice:
- Significantly elevated blood pressure readings at home
- Severe or unusual fatigue, weakness, or pallor that worsens (possible drop in hemoglobin or PRCA)
- New or worsening headaches, vision changes, or dizziness
- Signs of infection at the injection site (redness, swelling, warmth)
Pure Red Cell Aplasia (PRCA): A Rare but Serious Risk
In rare cases, patients on Retacrit can develop Pure Red Cell Aplasia (PRCA) — a condition where the bone marrow stops producing red blood cells due to the development of antibodies that neutralize epoetin alfa. PRCA is most commonly seen in CKD patients receiving ESAs by subcutaneous injection. Signs include sudden, severe anemia (very low hemoglobin) and very low reticulocyte count. If suspected, Retacrit must be stopped immediately and your prescriber must evaluate for PRCA.
The Bottom Line
Retacrit is a powerful medication with a well-documented safety profile. Most patients tolerate it well when their hemoglobin is kept in the target range and blood pressure is monitored. The most important rules: take your blood pressure seriously, don't skip scheduled lab work, and always report unusual symptoms to your prescriber immediately. For more, see our guide on Retacrit drug interactions. And if you need help finding your Retacrit prescription, medfinder can help.
Frequently Asked Questions
High blood pressure (hypertension) is the most common side effect of Retacrit. Approximately 25% of dialysis patients who start Retacrit require new or increased antihypertensive therapy. Blood pressure should be monitored regularly and controlled before starting Retacrit.
Yes. Retacrit carries an FDA boxed warning for increased risk of blood clots (thromboembolism), including deep vein thrombosis (DVT), pulmonary embolism, and thrombosis of dialysis vascular access. This risk is higher when hemoglobin is driven above 11 g/dL — which is why the lowest effective dose is always used.
Pure Red Cell Aplasia (PRCA) is a rare but serious condition where the body develops antibodies against epoetin alfa, causing the bone marrow to stop making red blood cells. It's most associated with subcutaneous injection in CKD patients. Signs are sudden severe anemia. PRCA is rare — but if you notice your symptoms worsening suddenly, tell your doctor immediately.
There is FDA-required labeling stating that ESAs including Retacrit have been shown to shorten survival and increase tumor progression in certain cancer types (breast, NSCLC, head and neck, lymphoid, cervical) in clinical studies. This is why Retacrit should only be used in cancer patients receiving myelosuppressive chemotherapy without curative intent — not for all cancer patients.
Injection site reactions (pain, irritation) typically resolve within a few days. Flu-like symptoms (fever, muscle aches) that may occur early in treatment often improve within the first few weeks. Hypertension may persist as long as you are on Retacrit and needs ongoing management. Always contact your prescriber if side effects are severe or worsening.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Retacrit also looked for:
More about Retacrit
30,351 have already found their meds with Medfinder.
Start your search today.





